PDF herunterladen
TumorDiagnostik & Therapie 2020; 41(06): 371-374
DOI: 10.1055/a-1132-1640
Schwerpunkt Nierenzell- und urologische Tumoren

Medikamentöse Therapie beim kastrationsresistenten Prostatakarzinom

Friedemann Zengerling
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Während beim hormonsensitiven Prostatakarzinom die Kombinationstherapien auf dem Weg zum Behandlungsstandard sind, sind beim CRPC bisher nur Monotherapien zugelassen. Dieser Artikel stellt die derzeit zugelassenen Therapien vor und ordnet sie in die Therapiesequenz des CRPC ein.

Publikationsverlauf

Artikel online veröffentlicht:
03. August 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg). Krebs in Deutschland für 2015/2016. 12. Ausgabe. Berlin: 2019. doi:10.25646/5977 ISBN: 978-3-89606-298-7
    Google Scholar
  • 2 Heidenreich A. Therapy of hormone-refractory prostate cancer. Der Urologe Ausg A 2005; 44: 1481-1494 ; quiz 1495. doi:10.1007/s00120-005-0980-8
    CrossrefPubMedGoogle Scholar
  • 3 Palmberg C, Koivisto P, Visakorpi T. et al. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. European urology 1999; 36: 191-196
    CrossrefPubMedGoogle Scholar
  • 4 de Bono JS, Logothetis CJ, Molina A. et al Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine 2011; 364: 1995-2005 . doi:10.1056/NEJMoa1014618
    CrossrefPubMedGoogle Scholar
  • 5 Ryan CJ, Smith MR, Fizazi K. et al Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-160 . doi:10.1016/s1470-2045(14)71205-7
    CrossrefPubMedGoogle Scholar
  • 6 Scher HI, Fizazi K, Saad F. et al Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine 2012; 367: 1187-1197 . doi:10.1056/NEJMoa1207506
    CrossrefPubMedGoogle Scholar
  • 7 Beer TM, Armstrong AJ, Rathkopf DE. et al Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine 2014; 371: 424-433 . doi:10.1056/NEJMoa1405095
    CrossrefPubMedGoogle Scholar
  • 8 Tannock IF, de Wit R, Berry WR. et al Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine 2004; 351: 1502-1512 . doi:10.1056/NEJMoa040720
    CrossrefPubMedGoogle Scholar
  • 9 Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T. et al 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14: 117-124 . doi:10.1016/S1470-2045(12)70537-5
    CrossrefPubMedGoogle Scholar
  • 10 Vale CL, Burdett S, Rydzewska LHM. et al Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. The Lancet Oncology 2016; 17: 243-256 . doi:10.1016/S1470-2045(15)00489-1
    CrossrefPubMedGoogle Scholar
  • 11 de Bono JS, Oudard S, Ozguroglu M. et al Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England) 2010; 376: 1147-1154 . doi:10.1016/s0140-6736(10)61389-x
    CrossrefPubMedGoogle Scholar
  • 12 Eisenberger M, Hardy-Bessard AC, Kim CS. et al Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol 2017; 35: 3198-3206 . doi:10.1200/jco.2016.72.1076
    CrossrefPubMedGoogle Scholar
  • 13 Thibault C, Eymard JC, Birtle A. et al Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. Eur J Cancer 2018; 97: 41-48 . doi:10.1016/j.ejca.2018.03.008
    CrossrefPubMedGoogle Scholar
  • 14 Parker C, Nilsson S, Heinrich D. et al Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223 . doi:10.1056/NEJMoa1213755
    CrossrefPubMedGoogle Scholar
  • 15 Smith M, Parker C, Saad F. et al Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2019; 20: 408-419 . doi:10.1016/S1470-2045(18)30860-X
    CrossrefPubMedGoogle Scholar
  • 16 Rahbar K, Ahmadzadehfar H, Kratochwil C. et al German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. Journal of Nuclear Medicine 2017; 58: 85-90 . doi:10.2967/jnumed.116.183194
    PubMedGoogle Scholar
  • 17 Kantoff PW, Higano CS, Shore ND. et al Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422 . doi:10.1056/NEJMoa1001294
    CrossrefPubMedGoogle Scholar
  • 18 de Bono J, Mateo J, Fizazi K. et al Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020; 382: 2091-2102 . doi:10.1056/NEJMoa1911440
    CrossrefPubMedGoogle Scholar
  • 19 Robinson D, Van Allen EM, Wu YM. et al Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215-1228 . doi:10.1016/j.cell.2015.05.001
    CrossrefPubMedGoogle Scholar
  • 20 Epstein JI, Amin MB, Beltran H. et al Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014; 38: 756-767 . doi:10.1097/pas.0000000000000208
    CrossrefPubMedGoogle Scholar
  • 21 Clermont PL, Ci X, Pandha H. et al Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. International Journal of Endocrine Oncology 2019; 6: IJE20 doi:10.2217/ije-2019-0008
    CrossrefPubMedGoogle Scholar